BridgeBio Pharma Inc

NASDAQ:BBIO 4:00:00 PM EDT

25.23

-0.40 (-1.56%)

: $25.23 0.00 (0.00%)

Market Cap (Intraday)	4.67B
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$1.67 Million
Adjusted EPS	-$0.93

See more estimates

10-Day MA	$25.37
50-Day MA	$26.03
200-Day MA	$29.45

See more pivots

BridgeBio Pharma Inc Stock, NASDAQ:BBIO

3160 Porter Drive, Suite 250, Palo Alto, California 94304

United States of America

Phone: +1.650.391.9740

Number of Employees: 550

http://www.bridgebio.com

Description

BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.